Denmark reimburses three new drugs
This article was originally published in Scrip
Executive Summary
The Danish Medicines Agencyhas approved three new drugs for general reimbursement: UCB's Vimpat (lacosamide) for the treatment of epilepsy, Indexus's Vantas (histrelin) for the treatment of prostate cancer, and Eli Lilly's Cymbalta (duloxetine hydrochloride) for the treatment of depression, anxiety, stress urinary incontinence (SUI) and diabetic peripheral neuropathic pain (DPNP), with restrictions. Reimbursement decisions are based on section 144 of the Danish Health Act. The Agency reimbursed 24 medicines and declined to reimburse five during 2008.